作者
Jürgen K Rockstroh, Karine Lacombe, Rolando M Viani, Chloe Orkin, David Wyles, Anne F Luetkemeyer, Ruth Soto-Malave, Robert Flisiak, Sanjay Bhagani, Kenneth E Sherman, Tatiana Shimonova, Peter Ruane, Joseph Sasadeusz, Jihad Slim, Zhenzhen Zhang, Suvajit Samanta, Teresa I Ng, Abhishek Gulati, Matthew P Kosloski, Nancy S Shulman, Roger Trinh, Mark Sulkowski
发表日期
2018/9/14
期刊
Clinical Infectious Diseases
卷号
67
期号
7
页码范围
1010-1017
出版商
Oxford University Press
简介
Background
Once-daily glecaprevir coformulated with pibrentasvir (glecaprevir/pibrentasvir) demonstrated high rates of sustained virologic response 12 weeks after treatment (SVR12) in patients with hepatitis C virus (HCV) genotype 1–6 infection. This phase 3 study evaluated the efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV genotype 1–6 and human immunodeficiency virus type 1 (HIV-1) coinfection, including patients with compensated cirrhosis.
Methods
EXPEDITION-2 was a phase 3, multicenter, open-label study evaluating glecaprevir/pibrentasvir (300 mg/120 mg) in HCV genotype 1–6/HIV-1–coinfected adults without and with compensated cirrhosis for 8 and 12 weeks, respectively. Patients were either HCV treatment-naive or experienced with sofosbuvir, ribavirin, or interferon, and antiretroviral therapy (ART) naive or on a stable ART …
学术搜索中的文章
JK Rockstroh, K Lacombe, RM Viani, C Orkin, D Wyles… - Clinical Infectious Diseases, 2018